目的 研究孟鲁司特联合布地奈德治疗哮喘患儿的临床疗效。方法 选取2013年5月-2015年5月儿科收集治疗的100例哮喘患儿作为研究对象，按照随机奇偶数字法分为治疗组和对照组，各50例；对照组患儿行布地奈德雾化治疗，治疗组患儿加用孟鲁司特治疗；分析比较两组治疗情况、肺功能改善、不良反应等。结果 两组肺功能比较，组内治疗后优于治疗前，差异显著（P<0.05）；治疗后治疗组高于对照组，差异显著（P<0.05）；治疗组憋醒天数、咳嗽评分、哮喘评分均短于对照组，差异显著（P<0.05）；不良反应率比较：治疗组14.0%低于对照组30.0%，差异显著（P<0.05）。结论 孟鲁司特联合布地奈德对哮喘患儿的治疗可明显改善患儿肺功能，控制哮喘症状，且无严重不良反应，具有较高的临床应用价值。

Objective To explore the clinical medication efficacy of montelukast for the treatment of children with asthma. Methods One hundred children with asthma admitted and treated by the Department of Pediatrics from May, 2013 to May, 2015 were selected as research subjects, who were divided into the treatment group and the control group according to random even-odd method with 50 cases in each group. Patients in the control group were subject to budesonide nebulization therapy, and patients in the treatment group were subject to montelukast plus treatment on the basis of that applied on patients in the control group. The treatment conditions, improvements of lung function and adverse reactions of patients in two groups were compared. Results Comparison in lung function of patients in two groups, the efficacy on patients after intra-group treatment was better than that before treatment, and the differences were significant (P<0.05). Indexes of patients in the treatment group after treatment were better than that of patients in the control group (P<0.05), and the difference was significant. The suppressive waken days, asthma score, and cough score of patients in the treatment group were shorter than those of patients in the control group (P<0.05), and the difference was significant. The comparison in the rate of adverse reactions was as follows: The rate of adverse reactions in the treatment group was 14.0% lower than that of patients in the control group at 30% (P<0.05), and the difference was significant. Conclusion The treatment for budesonide on children with asthma can obviously improve lung function and control symptoms of asthma without serious adverse reactions, delivering high clinical value.